Silence Therapeutics Plc: Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Silence Therapeutics Plc is a biotechnology company focused on discovering and developing RNA therapeutics (siRNA) for cardiovascular, hematology, and rare diseases. The company operates as a single reportable segment. Effective January 1, 2025, the company transitioned from a foreign private issuer to a domestic filer, changing its reporting currency from GBP to USD and adopting U.S. GAAP retrospectively.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0.14 million | $15.70 million |
| Net Loss | $(28.53) million | $(2.31) million |
| Operating Loss | $(28.41) million | $(5.58) million |
| R&D Expenses | $(20.81) million | $(11.85) million |
| Cash & Short-Term Investments | $136.53 million | $168.73 million (implied) |
| Operating Cash Flow | $(12.31) million | $(9.14) million |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.02) |
Note: The filing does not provide a specific gross margin percentage due to the negligible revenue relative to costs. The company has no commercial product sales; revenue is derived from collaboration agreements.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 99% to $0.14 million from $15.70 million in Q1 2024. This was primarily due to the absence of milestone payments from the AstraZeneca collaboration in Q1 2025 (compared to $14.7 million recognized in Q1 2024) and the conclusion of the Mallinckrodt and Hansoh collaborations.
- Increased R&D Spend: Research and development costs increased by $9.0 million (76%) to $20.81 million, driven by the advancement of clinical trials (specifically the SANRECO study for divesiran) and increased contract manufacturing activities.
- Foreign Currency Impact: The company recorded a foreign currency loss of $3.77 million, compared to a gain of $0.35 million in the prior year, largely due to exchange rate fluctuations between the USD, GBP, and EUR.
- Collaboration Status: The Hansoh collaboration concluded in December 2024 with no further development. The Mallinckrodt collaboration concluded in March 2024. The AstraZeneca collaboration remains active, with revenue recognized based on the cost-to-cost method.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($136.5 million) are sufficient to fund operations into 2028, assuming anticipated milestone payments of $20 million are received from existing collaborations.
- Product Pipeline:
- Divesiran (SLN124): Phase 2 SANRECO trial for polycythemia vera (PV) is underway; Phase 1 results showed reduced phlebotomy requirements. FDA Fast Track and Orphan Drug designations granted.
- Zerlasiran (SLN360): Phase 3 readiness activities are on track for mid-2025. Partnering discussions for Phase 3 development are ongoing.
- Risks:
- Capital Needs: The company expects to incur losses for the foreseeable future and will require additional funding to support clinical development and commercialization.
- Regulatory & Data Privacy: Significant risks exist regarding data privacy laws (GDPR, CCPA) and cross-border data transfers, which could lead to fines or operational disruptions.
- Collaboration Dependency: Future funding relies partly on milestone payments from partners (e.g., AstraZeneca), which are contingent on achieving specific development or regulatory objectives.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase 2 SANRECO trial for divesiran.
- Confirm the status of partnership discussions for zerlasiran Phase 3 development.
- Monitor the company's cash burn rate against the projected runway into 2028.
- Review the specific milestones required to trigger the anticipated $20 million in future payments from AstraZeneca.
- Assess the impact of the transition to U.S. GAAP and domestic filer status on future reporting and compliance costs.